A postmarketing clinical study of milnacipran hydrochloride (MIL001) for the treatment of depression. -a double-blind parallel-group design, using a comparator of paroxetine hydrochloride hydrate-

Trial Profile

A postmarketing clinical study of milnacipran hydrochloride (MIL001) for the treatment of depression. -a double-blind parallel-group design, using a comparator of paroxetine hydrochloride hydrate-

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 May 2016

At a glance

  • Drugs Milnacipran (Primary) ; Paroxetine
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Asahi Kasei Pharma Corp
  • Most Recent Events

    • 25 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top